MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Location
Founded
1989-12-19
Website
Risk Signals
4874 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Surgical and Medical Instruments and Apparatus, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Live alerts from global media, monitored by Business Radar
2025-03-01 (cardiovascularbusiness.com)
Week in Review: Pacemakers recalled | FDA ends semaglutide shortage | Researchers target Lp(a) | Comparing popular TAVR valves | Cardiovascular Business
The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan.
Read more
2025-02-28 (cardiovascularbusiness.com)
Comparing popular TAVR valves | Teleflex to acquire Biotronik assets for $791M | FDA sued over semaglutide | Google's good news | Cardiovascular Business
The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan.
Read more
2025-02-26 (cardiovascularbusiness.com)
Medtronic enrolls first patient in new coronary DCB trial—data could lead to FDA approval
The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan.
Read more
2025-02-26 (bloombergtax.com)
Health-Care Companies Must Prep to Pass Transfer Pricing Tests
Moss Adams' Vernon Noronha and Felicita Moreno-Stevens say health-care and medical device companies need to consider Loper Bright's effects and global tax regulations when trying to adapt to international trade changes.
Read more
2025-02-08 (marketbeat.com)
Cantor Fitzgerald Investment Advisors L.P. Cuts Stake in Medtronic plc (NYSE:MDT)
Cantor Fitzgerald Investment Advisors L.P. reduced its holdings in shares of Medtronic plc (NYSE:MDT - Free Report) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 204,498
Read more
2025-02-06 (marketbeat.com)
Sargent Investment Group LLC Invests $453,000 in Medtronic plc (NYSE:MDT)
Sargent Investment Group LLC acquired a new stake in Medtronic plc (NYSE:MDT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,544 shares of the medical technology company's stock, valued a
Read more
2025-01-31 (marketbeat.com)
Boomfish Wealth Group LLC Cuts Position in Medtronic plc (NYSE:MDT)
Boomfish Wealth Group LLC cut its holdings in Medtronic plc (NYSE:MDT - Free Report) by 36.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,413 shares of the medical technology company's stock after selling 5,328 shares during the quart
Read more
2025-01-30 (benzinga.com)
Breaking Update: Matthew Walter Engages In Options Exercise At Medtronic Realizing $23K - Medtronic (NYSE:MDT) -
Matthew Walter, SVP at Medtronic MDT, reported a large exercise of company stock options on January 28, according to a new SEC filing.
Read more
2025-01-30 (benzinga.com)
Insider Activity Update: Geoffrey Martha Executes Options Exercise, Resulting In $618K At Medtronic - Medtronic (NYSE:MDT) -
Disclosed in a recent SEC filing on January 28, Martha, Chairman and CEO at Medtronic MDT, made a noteworthy transaction involving the exercise of company stock options.
Read more